» Articles » PMID: 16396836

Down-regulation of Interferon Regulatory Factor 4 Gene Expression in Leukemic Cells Due to Hypermethylation of CpG Motifs in the Promoter Region

Overview
Specialty Biochemistry
Date 2006 Jan 7
PMID 16396836
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Although the bcr-abl translocation has been shown to be the causative genetic aberration in chronic myeloid leukemia (CML), there is mounting evidence that the deregulation of other genes, such as the transcription factor interferon regulatory factor 4 (IRF-4), is also implicated in the pathogenesis of CML. Promoter methylation of CpG target sites or direct deletions/insertions of genes are mechanisms of a reversible or permanent silencing of gene expression, respectively. Therefore, we investigated whether IRF-4 promoter methylation or mutation may be involved in the regulation of IRF-4 expression in leukemia cells. Whereas promoter mutations or structural rearrangements could be excluded as a cause of altered IRF-4 expression in hematopoietic cells, the IRF-4 promoter methylation status was found to significantly influence IRF-4 transcription. First, treatment of IRF-4-negative lymphoid, myeloid and monocytic cell lines with the methylation-inhibitor 5-aza-2-deoxycytidine resulted in a time- and concentration-dependent increase of IRF-4 mRNA and protein levels. Second, using a restriction-PCR-assay and bisulfite-sequencing we identified specifically methylated CpG sites in IRF-4-negative but not in IRF-4-positive cells. Third, we clearly determined promoter methylation as a mechanism for IRF-4 down-regulation via reporter gene assays, but did not detect an association of methylational status and mRNA expression of DNA methyltransferases or methyl-CpG-binding proteins. Together, these data suggest CpG site-specific IRF-4 promoter methylation as a putative mechanism of down-regulated IRF-4 expression in leukemia.

Citing Articles

Research and analysis of differential gene expression in CD34 hematopoietic stem cells in myelodysplastic syndromes.

Wang M, Liao C, Wei X, Xie Y, Han P, Yu Y PLoS One. 2025; 20(3):e0315408.

PMID: 40073065 PMC: 11902259. DOI: 10.1371/journal.pone.0315408.


Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia.

Zhong F, Yao F, Yang Y, Liu J, Li M, Jiang J Cancer Cell Int. 2023; 23(1):61.

PMID: 37024911 PMC: 10080819. DOI: 10.1186/s12935-023-02905-x.


The dynamic functions of IRF4 in B cell malignancies.

Maffei R, Fiorcari S, Atene C, Martinelli S, Mesini N, Pilato F Clin Exp Med. 2022; 23(4):1171-1180.

PMID: 36495369 PMC: 10390622. DOI: 10.1007/s10238-022-00968-0.


Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Wu J, Leng X, Pan Z, Xu L, Zhang H Int J Gen Med. 2021; 14:5675-5692.

PMID: 34557022 PMC: 8454526. DOI: 10.2147/IJGM.S328225.


Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.

Young G, Symonds E, Nielsen H, Ferm L, Christensen I, Dekker E Clin Epigenetics. 2021; 13(1):14.

PMID: 33478584 PMC: 7818774. DOI: 10.1186/s13148-020-00999-y.


References
1.
Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A . Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999; 13(11):1812-6. DOI: 10.1038/sj.leu.2401563. View

2.
Amaravadi L, Klemsz M . DNA methylation and chromatin structure regulate PU.1 expression. DNA Cell Biol. 2000; 18(12):875-84. DOI: 10.1089/104454999314737. View

3.
Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

4.
Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I . MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000; 14(3):449-56. DOI: 10.1038/sj.leu.2401696. View

5.
Baylin S, Herman J . DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000; 16(4):168-74. DOI: 10.1016/s0168-9525(99)01971-x. View